News

NBTS Brain Tumor Clinical Trials Report: Q1 2021 It can be hard to keep track of new clinical trial opportunities opening across the United States, especially during the current public health crisis created by the coronavirus (COVID-19). However, there are many clinical trials still actively enrolling patients, and this report provides a summary of the studies that have recently opened or started for […] April 8, 2021

New Treatment Arms Opening for Patients in NBTS-Funded GBM AGILE Clinical Trial Yesterday, it was announced that the GBM AGILE adaptive clinical trial platform is opening two new treatment arms, with one evaluating Kintara Therapeutics’s chemotherapy, VAL-083, and Kazia Therapeutics’s targeted therapy, paxalisib.  “NBTS has long supported GBM AGILE as a scientifically cutting-edge and more patient-friendly way to develop and evaluate emerging new treatments for patients,” says […] January 7, 2021

4 Big Takeaways From the 2020 Annual Meeting of the Society for Neuro-Oncology A move to a virtual platform didn’t diminish the quality of the 2020 Annual Meeting of the Society for Neuro-Oncology (SNO), the yearly gathering of the world’s foremost brain tumor researchers and clinicians. As usual, the National Brain Tumor Society was a proud platinum sponsor of this important conference and deployed our own team of […] December 19, 2020

Introducing the NBTS Personalized Support and Navigation Program For years, the National Brain Tumor Society has offered our assistance to patients and caregivers who’ve reached out in need of support, guidance, and/or other resources to help navigate a brain tumor diagnosis and the subsequent treatment experience. While a number of sources for direct patient services exist for brain tumor patients, our new NBTS […] April 17, 2020

Can Newly Approved “Tissue Agnostic” Drugs Benefit Pediatric High-grade Glioma Patients? Recently, the U.S. Food and Drug Administration (FDA) granted accelerated approval* to the drug Rozlytrek (entrectinib, Genentech/Roche**) as a treatment for patients, 12 years or older, whose tumors have a specific genetic defect known as an “NTRK gene fusion.”*** This is now the second drug that the FDA has approved to treat patients with this […] September 16, 2019